Search

Your search keyword '"Amber B. Koehler"' showing total 3 results
Start Over Author "Amber B. Koehler" Publisher wiley
3 results on '"Amber B. Koehler"'

1. The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice

Author

Sameer A. Parikh, Sara J. Achenbach, Timothy G. Call, Kari G. Rabe, Wei Ding, Jose F. Leis, Saad S. Kenderian, Asher A. Chanan‐Khan, Amber B. Koehler, Susan M. Schwager, Eli Muchtar, Amie L. Fonder, Kristen B. McCullough, Adrienne N. Nedved, Matthew D. Smith, Susan L. Slager, Neil E. Kay, Heidi D. Finnes, and Tait D. Shanafelt

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract To study the impact of dose modification and temporary interruption of ibrutinib in routine clinical practice, we conducted a retrospective study of consecutive CLL patients treated with ibrutinib outside the context of a clinical trial at Mayo Clinic, (Rochester, MN) from 11/2013 to 12/2017. Of 209 patients, 131 (74%) had unmutated IGHV, 38 (20%) had TP53 disruption, and 47 (22%) were previously untreated. A total of 87/209 (42%) patients started reduced dose ibrutinib (

Published
2020
Full Text
View/download PDF

2. <scp>DTRMWXHS</scp> ‐12, a novel Bruton tyrosine kinase inhibitor, in combination with everolimus and pomalidomide in patients with relapsed/refractory lymphomas: An open‐label, multicenter, phase 1a/1b study

Author

Scott F. Huntington, Stephen J. Schuster, Wei Ding, Amber B. Koehler, Danielle M. Brander, Allison C. Rosenthal, Jose F. Leis, Han W. Tun, Muhamad Alhaj Moustafa, Madiha Iqbal, Wei He, Albert S. Kearney, Timothy P. McKinlay, Min Gui, and Anthony R. Mato

Subjects
Hematology
Published
2023

3. Humoral and cellular immune responses to recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosis

Author

Michael J. Johnson, Sameer A. Parikh, Paul J. Hampel, Timothy G. Call, Jose F. Leis, Jennifer Canniff, Wei D Ding, Congrong Miao, Jennifer A Whitaker, Matthew A. Holets, Richard B. Kennedy, Kari G. Rabe, Neil E. Kay, Heather C. Darby, Eli Muchtar, Myron J. Levin, Saad S. Kenderian, D. Scott Schmid, Yucai Wang, Adriana Weinberg, Amber B. Koehler, Susan L. Slager, and Suzanne R. Hayman

Subjects
Adult, Male, Chronic lymphocytic leukemia, Lymphocytosis, Herpes Zoster, Article, Hypogammaglobulinemia, hemic and lymphatic diseases, medicine, Herpes Zoster Vaccine, Humans, B cell, Aged, Aged, 80 and over, B-Lymphocytes, Immunity, Cellular, biology, business.industry, Antibody titer, Hematology, Middle Aged, medicine.disease, Leukemia, Lymphocytic, Chronic, B-Cell, Immunity, Humoral, Vaccination, medicine.anatomical_structure, Immunology, biology.protein, Monoclonal B-cell lymphocytosis, Female, Zoster vaccine, Antibody, business, medicine.drug
Abstract

Monoclonal B cell lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL) are clonal B cell disorders associated with increased risk of infections and impaired vaccination responses. We investigated the immunogenicity of recombinant zoster vaccine (RZV) in these patients. Individuals with MBL/untreated CLL and Bruton tyrosine kinase inhibitor (BTKi)-treated CLL patients were given two doses of RZV separated by two months. Responses assessed at 3-months and 12-months from the first dose of RZV by an anti-glycoprotein E ELISA antibody assay and by dual-color IFN-γ and IL-2 FLUOROSPOT assays were compared to historic controls matched by age and sex. Sixty-two patients (37 MBL/untreated CLL and 25 BTKi-treated CLL) were enrolled with a median age of 68 years at vaccination. An antibody response at 3 months was seen in 45% of participants, which was significantly lower compared to historic controls (63%, P=0.03). The antibody response did not significantly differ between MBL/untreated CLL and BTKi-treated CLL (51% vs 36%, respectively, P=0.23). The CD4+ T cell response to vaccination was significantly lower in study participants compared to controls (54% vs 96%, P

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results